Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Part of paid clinical trials in Bridgeport, Connecticut.

Sponsor
Amgen
Study ID
NCT07293260
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Cardiovascular Disease

Eligibility Criteria

Sex
ALL
Age
35 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Olpasiran — DRUG
    Olpasiran will be administered SC.
  • Placebo — DRUG
    Placebo will be administered SC.

Study Details

The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).

Key Dates

Start date
Mar 23, 2026
Status verified
Apr 2026
Primary completion
Jun 15, 2028
Completion
Jun 15, 2028

Study Design

Enrollment
406 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Olpasiran
    Participants will receive olpasiran subcutaneously (SC) once every 12 weeks (Q12W).
  • Placebo Comparator: Placebo
    Participants will receive placebo SC Q12W.

Primary Outcome Measure

Change in NCP Volume from Baseline to Week 72 [ Time Frame: Baseline to Week 72 ]

Central Contacts

Locations (6)

FacilityCityStateZIPSite coordinators
Bridgeport HospitalBridgeportConnecticut06610-
Jacksonville Center for Clinical ResearchJacksonvilleFlorida32216-
Midwest Heart and Vascular SpecialistsOverland ParkKansas66211-
Flourish BowieBowieMaryland20715-
Montefiore Medical Center - BronxPhiladelphiaPennsylvania19141-
Vital Heart and VeinHumbleTexas77338-

Find similar trials in Bridgeport, CT

By research site
Bridgeport Hospital· Bridgeport, CTJacksonville Center for Clinical Research· Jacksonville, FLMidwest Heart and Vascular Specialists· Overland Park, KSFlourish Bowie· Bowie, MDMontefiore Medical Center - Bronx· Philadelphia, PAVital Heart and Vein· Humble, TX

Related Studies